Difference between revisions of "Team:NCTU Formosa/Description"
Line 71: | Line 71: | ||
background-image:url("https://static.igem.org/mediawiki/2015/0/0e/NCTU_Formosa_backgorund_test.png"); | background-image:url("https://static.igem.org/mediawiki/2015/0/0e/NCTU_Formosa_backgorund_test.png"); | ||
background-repeat:no-repeat; | background-repeat:no-repeat; | ||
− | background-position:10px | + | background-position:10px 60px; |
position:relative; | position:relative; | ||
height:70vh; | height:70vh; |
Revision as of 13:46, 17 September 2015
APPOllO E.Cotector
To enhance the efficiency of diagnosis and provide reference for proper usage of targeted drugs and combination therapy, we come up with the idea of detecting multimarker at the same time and this was how our marvelous E.Cotector was born. This year, NCTU_Formosa commits to creating a multimarker diagnosis platform via scFv as probes for helping physicians to determine and prescribe the usage of targeted drugs in cancer patients, especially the monoclonal-antibody-targeted drugs.
Customized Detection Platform
This year, APOllO, introduce a revolution customized detecting platform. We call it the E.Cotector.
We built three individual biobrick libraries of scFv probes, color signals and Gold Binding Polypeptide (GBP) for the customized detection platform. Probes detect the target we want. Fluorescence protein or chromoprotein expresses signal for observation. GBP acts as a bridge to connect our product to gold, which enables our product to be applied to biosensors. Our customers can spontaneously choose from our libraries, pair up any biobricks. Next, comes the most crucial part of our project. Our team will then co-transform the plasmids into E. coli. Our customized detection platform, The APOllO E.Cotector, is therefore born. By co-transforming plasmids, it not only helps us customize our product every which way for our customers but also brings us a major advantage in our manufacturing procedure. We no longer have to build lengthy biobricks, which tremendously increases our manufacturing efficiency.
Single chain variable fragment as probe
In our product, we chose Single chain variable fragment (scFv) Abs as probes to detect. ScFv are one of the recombinant antibody (rAb) fragments, which are popular therapeutic alternatives to full length monoclonal Abs. Compared to generating whole Abs from animal cell culture, scFv are smaller and can be expressed rapidly, economically and in large quantities in a bacterial host, such as E. coli. A scFv possesses the complete antigen binding site, which contains the variable heavy (VH) and variable light domain of an antibody. The VH domain is linked to a VL domain by an introduced flexible polypeptide linker. A scFv is capable of binding to the target antigens with an affinity similar to that of the parent mAb. Since scFv fragments contain specific a